Attacking disease from all angles

Antibodies are the protectors of the immune system – recognizing and neutralizing foreign substances like bacteria and viruses. But for 3% of the world’s population, antibodies turn and begin attacking one’s own healthy organs and systems – or in pregnancy, one’s fetus – becoming autoantibodies or alloantibodies (in pregnancy). These autoantibodies are the driving force behind 80+ different diseases, most of which don’t have safe, effective, approved targeted therapies (National Library of Medicine).

Our potential therapy has a unique tolerability profile for patients living with autoantibody disease and those affected by alloantibody conditions during pregnancy.

Our targeted approach is believed to help unlock the potential to address unmet needs across autoantibody driven diseases. Johnson & Johnson is tackling three key segments in the autoantibody space including Rare Autoantibody diseases, Prevalent Rheumatic diseases mediated by autoantibody complexes, and — uniquely — Maternal Fetal diseases mediated by maternal alloantibodies. All are unified by immense unmet patient need.

Where most would follow the concept of one drug for one disease and target the single biggest, or least complex, autoantibody disease – we had to think differently. Systemically. Boldly. Because drug development is built on hope. And all of us at J&J Innovative Medicine believe in a transformative answer to this massive unmet need.